Nanobiotix: Voting Rights and Shares Capital of the Company

Rhea-AI Summary

On August 31, 2022, Nanobiotix reported a total of 34,875,872 shares outstanding, with voting rights totaling 36,274,272 theoretical rights and 36,250,130 exercisable rights. This announcement aligns with regulations from the French Financial Markets Authority, ensuring transparency in shareholder voting. Nanobiotix focuses on innovative therapeutic approaches for cancer treatment, utilizing its nanoparticle technology, specifically targeting head and neck cancers. Investors can find further details on their official website.

Positive

• Engagement in innovative cancer therapeutics with a proprietary nanoparticle platform.
• Focus on enhancing treatment outcomes for solid tumors, particularly head and neck cancers.

Negative

• None.

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS--(BUSINESS WIRE)-- Regulatory News:

Nanobiotix (Paris:NANO) (NASDAQ:NBTX):

Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date	Number of Shares Outstanding	Total number of voting rights
		Total voting rights, theoretical (1)	Total voting rights, exercisable (2)
August 31, 2022	34,875,872	36,274,272	36,250,130

⁽¹⁾ The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

⁽²⁾ The total number of exercisable at a Shareholders’ Meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

***

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005576/en/

Nanobiotix



Nanobiotix Communications

Brandon Owens

VP, Communications

+1 (617) 852-4835

contact@nanobiotix.com

Nanobiotix Investor Relations

Kate McNeil

SVP, Investor Relations

+1 (609) 678-7388

investors@nanobiotix.com

Media Relations



France – Ulysse Communication

Pierre-Louis Germain

+ 33 (0) 6 64 79 97 51

plgermain@ulysse-communication.com

LifeSci Advisors

Ligia Vela-Reid

+44 (0) 7413825310

lvela-reid@lifesciadvisors.com

Source: Nanobiotix

FAQ

What are the latest share statistics for Nanobiotix (NBTX)?

As of August 31, 2022, Nanobiotix has 34,875,872 shares outstanding, 36,274,272 theoretical voting rights, and 36,250,130 exercisable voting rights.

What therapeutic focus does Nanobiotix have?

Nanobiotix is focusing on developing treatments for solid tumors, with an initial emphasis on head and neck cancers.

Where is Nanobiotix listed?

Nanobiotix is listed on Euronext Paris and NASDAQ under the ticker NBTX.

Who should I contact for investor relations at Nanobiotix?

For investor relations inquiries, contact Kate McNeil, SVP, Investor Relations, at investors@nanobiotix.com.